Fig. 5From: Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseasesQualification of the UC-MSC-based ATMP manufacturing process. A Quantities and proliferation data of UC-MSCs from P0 to P3. B Quality controls performed during MCS (n = 2 batches) and WCS steps (n = 3 batches)Back to article page